modafinil
Adjunctive therapy • Brands: Provigil
Last reviewed: 2025-12-30
General information
- Class: Adjunctive therapy
- Common US brands: Provigil
- Therapeutic drug monitoring not routinely recommended.
- Last reviewed: 2025-12-30
Dosing & forms
- Forms/strengths: —
- Frequency: —
- Food: —
- Typical range: —
Mechanism (brief)
Wakefulness-promoting agent used for excessive sleepiness in narcolepsy, obstructive sleep apnea, and shift work disorder; Schedule IV with important rash/hypersensitivity warnings and clinically relevant CYP3A4 induction and CYP2C19 inhibition interactions.
Metabolism & Half‑life
- Metabolism: CYP3A4, CYP2C19
- Half‑life: Steady-state mean 15 h
Therapeutic Drug Monitoring (TDM)
Recommended: No
Monitoring highlights
- —
Sources
- PROVIGIL (modafinil) tablets prescribing information — DailyMed (2025)
- Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials — Journal of Clinical Psychiatry (2013)
- AGNP TDM Consensus — Pharmacopsychiatry (2018)
- Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline — Journal of Clinical Sleep Medicine (2021)